001     124380
005     20240228145510.0
024 7 _ |a 10.1038/gim.2016.147
|2 doi
024 7 _ |a pmid:27711073
|2 pmid
024 7 _ |a pmc:PMC5382131
|2 pmc
024 7 _ |a 1098-3600
|2 ISSN
024 7 _ |a 1530-0366
|2 ISSN
024 7 _ |a altmetric:12511619
|2 altmetric
037 _ _ |a DKFZ-2017-01259
041 _ _ |a eng
082 _ _ |a 570
100 1 _ |a Muranen, Taru A
|0 0000-0002-5895-1808
|b 0
245 _ _ |a Genetic modifiers of CHEK2*1100delC-associated breast cancer risk.
260 _ _ |a Baltimore, Md.
|c 2017
|b Lippincott, Williams & Wilkins
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1660822376_27718
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a CHEK2*1100delC is a founder variant in European populations that confers a two- to threefold increased risk of breast cancer (BC). Epidemiologic and family studies have suggested that the risk associated with CHEK2*1100delC is modified by other genetic factors in a multiplicative fashion. We have investigated this empirically using data from the Breast Cancer Association Consortium (BCAC).Using genotype data from 39,139 (624 1100delC carriers) BC patients and 40,063 (224) healthy controls from 32 BCAC studies, we analyzed the combined risk effects of CHEK2*1100delC and 77 common variants in terms of a polygenic risk score (PRS) and pairwise interaction.The PRS conferred odds ratios (OR) of 1.59 (95% CI: 1.21-2.09) per standard deviation for BC for CHEK2*1100delC carriers and 1.58 (1.55-1.62) for noncarriers. No evidence of deviation from the multiplicative model was found. The OR for the highest quintile of the PRS was 2.03 (0.86-4.78) for CHEK2*1100delC carriers, placing them in the high risk category according to UK NICE guidelines. The OR for the lowest quintile was 0.52 (0.16-1.74), indicating a lifetime risk close to the population average.Our results confirm the multiplicative nature of risk effects conferred by CHEK2*1100delC and the common susceptibility variants. Furthermore, the PRS could identify carriers at a high lifetime risk for clinical actions.Genet Med advance online publication 06 October 2016.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Greco, Dario
|b 1
700 1 _ |a Blomqvist, Carl
|0 0000-0003-3041-1938
|b 2
700 1 _ |a Aittomäki, Kristiina
|b 3
700 1 _ |a Khan, Sofia
|0 0000-0003-4185-8882
|b 4
700 1 _ |a Hogervorst, Frans
|0 0000-0002-5883-9517
|b 5
700 1 _ |a Verhoef, Senno
|b 6
700 1 _ |a Pharoah, Paul D P
|0 0000-0001-8494-732X
|b 7
700 1 _ |a Dunning, Alison M
|0 0000-0001-6651-7166
|b 8
700 1 _ |a Shah, Mitul
|b 9
700 1 _ |a Luben, Robert
|b 10
700 1 _ |a Bojesen, Stig E
|b 11
700 1 _ |a Nordestgaard, Børge G
|b 12
700 1 _ |a Schoemaker, Minouk
|b 13
700 1 _ |a Swerdlow, Anthony
|0 0000-0001-5550-4159
|b 14
700 1 _ |a García-Closas, Montserrat
|b 15
700 1 _ |a Figueroa, Jonine
|b 16
700 1 _ |a Dörk, Thilo
|b 17
700 1 _ |a Bogdanova, Natalia V
|b 18
700 1 _ |a Hall, Per
|b 19
700 1 _ |a Li, Jingmei
|0 0000-0001-8587-7511
|b 20
700 1 _ |a Khusnutdinova, Elza
|b 21
700 1 _ |a Bermisheva, Marina
|b 22
700 1 _ |a Kristensen, Vessela
|b 23
700 1 _ |a Borresen-Dale, Anne-Lise
|b 24
700 1 _ |a Investigators, Nbcs
|b 25
700 1 _ |a Peto, Julian
|0 0000-0002-1685-8912
|b 26
700 1 _ |a Dos Santos Silva, Isabel
|b 27
700 1 _ |a Couch, Fergus J
|b 28
700 1 _ |a Olson, Janet E
|0 0000-0003-4944-7789
|b 29
700 1 _ |a Hillemans, Peter
|0 0000-0001-9829-3531
|b 30
700 1 _ |a Park-Simon, Tjoung-Won
|0 0000-0002-2863-3040
|b 31
700 1 _ |a Brauch, Hiltrud
|0 P:(DE-HGF)0
|b 32
700 1 _ |a Hamann, Ute
|0 0000-0001-6705-7624
|b 33
700 1 _ |a Burwinkel, Barbara
|0 P:(DE-He78)15b7fd2bc02d5ef47a2fe2dd0140d2bf
|b 34
700 1 _ |a Marme, Frederik
|b 35
700 1 _ |a Meindl, Alfons
|b 36
700 1 _ |a Schmutzler, Rita K
|b 37
700 1 _ |a Cox, Angela
|0 0000-0002-5138-1099
|b 38
700 1 _ |a Cross, Simon S
|b 39
700 1 _ |a Sawyer, Elinor J
|b 40
700 1 _ |a Tomlinson, Ian
|b 41
700 1 _ |a Lambrechts, Diether
|b 42
700 1 _ |a Moisse, Matthieu
|0 0000-0001-8880-9311
|b 43
700 1 _ |a Lindblom, Annika
|0 0000-0001-7675-7569
|b 44
700 1 _ |a Margolin, Sara
|b 45
700 1 _ |a Hollestelle, Antoinette
|0 0000-0003-1166-1966
|b 46
700 1 _ |a Martens, John W M
|b 47
700 1 _ |a Fasching, Peter A
|b 48
700 1 _ |a Beckmann, Matthias W
|b 49
700 1 _ |a Andrulis, Irene L
|b 50
700 1 _ |a Knight, Julia A
|b 51
700 1 _ |a Investigators, kConFab/Aocs
|b 52
700 1 _ |a Anton-Culver, Hoda
|b 53
700 1 _ |a Ziogas, Argyrios
|0 0000-0003-4529-3727
|b 54
700 1 _ |a Giles, Graham G
|b 55
700 1 _ |a Milne, Roger L
|b 56
700 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 57
700 1 _ |a Arndt, Volker
|0 P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0
|b 58
700 1 _ |a Mannermaa, Arto
|b 59
700 1 _ |a Kosma, Veli-Matti
|b 60
700 1 _ |a Chang, Jenny
|0 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
|b 61
700 1 _ |a Rudolph, Anja
|0 0000-0001-7520-2035
|b 62
700 1 _ |a Devilee, Peter
|0 0000-0002-8023-2009
|b 63
700 1 _ |a Seynaeve, Caroline
|b 64
700 1 _ |a Hopper, John L
|0 0000-0002-8567-173X
|b 65
700 1 _ |a Southey, Melissa C
|0 0000-0002-6313-9005
|b 66
700 1 _ |a John, Esther M
|b 67
700 1 _ |a Whittemore, Alice S
|b 68
700 1 _ |a Bolla, Manjeet K
|b 69
700 1 _ |a Wang, Qin
|0 0000-0002-9139-0627
|b 70
700 1 _ |a Michailidou, Kyriaki
|0 0000-0001-7065-1237
|b 71
700 1 _ |a Dennis, Joe
|0 0000-0003-4591-1214
|b 72
700 1 _ |a Easton, Douglas F
|0 0000-0003-2444-3247
|b 73
700 1 _ |a Schmidt, Marjanka K
|b 74
700 1 _ |a Nevanlinna, Heli
|b 75
773 _ _ |a 10.1038/gim.2016.147
|g Vol. 19, no. 5, p. 599 - 603
|0 PERI:(DE-600)2063504-7
|n 5
|p 599 - 603
|t Genetics in medicine
|v 19
|y 2017
|x 1530-0366
909 C O |p VDB
|o oai:inrepo02.dkfz.de:124380
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 32
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 33
|6 0000-0001-6705-7624
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 34
|6 P:(DE-He78)15b7fd2bc02d5ef47a2fe2dd0140d2bf
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 57
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 58
|6 P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 61
|6 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 62
|6 0000-0001-7520-2035
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Cancer risk factors and prevention
|x 0
914 1 _ |y 2017
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b GENET MED : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b GENET MED : 2015
920 1 _ |0 I:(DE-He78)B072-20160331
|k B072
|l Molekulargenetik des Mammakarzinoms
|x 0
920 1 _ |0 I:(DE-He78)C080-20160331
|k C080
|l Molekulare Epidemiologie
|x 1
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 2
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 3
920 1 _ |0 I:(DE-He78)G110-20160331
|k G110
|l Präventive Onkologie
|x 4
920 1 _ |0 I:(DE-He78)C071-20160331
|k C071
|l C071 Cancer Survivorship
|x 5
920 1 _ |0 I:(DE-He78)L801-20160331
|k L801
|l DKTK Tübingen
|x 6
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 7
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B072-20160331
980 _ _ |a I:(DE-He78)C080-20160331
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a I:(DE-He78)G110-20160331
980 _ _ |a I:(DE-He78)C071-20160331
980 _ _ |a I:(DE-He78)L801-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21